The plaintiffs and defendants in the ongoing litigation over testosterone replacement therapy drugs have joined forces in seeking to have the pending state court cases consolidated into a mass tort.
Late last week, Auxilium Pharmaceuticals and GlaxoSmithKline, which are being sued over claims that the testosterone medication they promoted caused a stroke, told the Philadelphia Court of Common Pleas that they support consolidating the pending litigation over the drugs into a mass tort.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
